Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

DNA Analysis

October 28, 2010 5:21 am | Drug Discovery & Development | Product Releases | Comments

ZyGEM Corp. Ltd., announced several developments supporting the advancement of its integrated microfluidics platform designed to dramatically decrease the time, complexity and cost of conducting DNA testing.

TOPICS:

Lead Optimization Tool

October 28, 2010 5:19 am | Product Releases | Comments

InhibOx Ltd announces LOx 2.0 - a flexible system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds.

TOPICS:

Stem Cells + Protein = Cancer

October 28, 2010 5:16 am | News | Comments

Researchers at North Carolina State University have found that the overproduction of a key protein in stem cells causes those stem cells to form cancerous tumors. Their work may lead to new treatments for a variety of cancers.

TOPICS:
Advertisement

Concerns Raised About 'Healthy' Antioxidants

October 28, 2010 5:14 am | News | Comments

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants — including those with the apparent ability to prevent cancer — may actually aggravate or even cause cancer in some individuals.

TOPICS:

GlobeImmune Expands GI-5005 Trial

October 28, 2010 5:11 am | News | Comments

GlobeImmune Inc. announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus infection. The company previously reported a 60% improvement in sustained virologic response.

TOPICS:

Ligocyte VLP Candidate Performs Well in Phase 1/2

October 28, 2010 5:08 am | News | Comments

LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company developing vaccine products, announced positive results from a Phase 1/2 challenge study of its norovirus virus-like particle (VLP) vaccine candidate.

TOPICS:

Sanofi Invests $10M In Regulus

October 28, 2010 5:05 am | News | Comments

Regulus Therapeutics Inc. announced that they have received a $10 million equity investment from sanofi-aventis. The investment makes sanofi-aventis the third investor in Regulus, along with its founding companies Alnylam and Isis.

TOPICS:

Michigan to Receive $4.7M of Glaxo Settlement

October 28, 2010 5:01 am | News | Comments

Michigan Attorney General Mike Cox says the state will get a $4.7 million share of a $750 million settlement of claims that GlaxoSmithKline distributed adulterated drugs.

TOPICS:
Advertisement

CDC Panel Recommends Meningitis Booster

October 28, 2010 5:00 am | by Mike Stobbe | News | Comments

Teens should get a booster dose of the vaccine for bacterial meningitis because a single shot doesn't work as long as expected, a federal advisory panel said.

TOPICS:

Gates Foundations Giving Millions in Seed Money

October 28, 2010 4:58 am | by Donna Gordon Blankinship | News | Comments

A night light that scares away mosquitoes possibly carrying malaria is among nine ideas the Bill & Melinda Gates Foundation thinks are worth more research dollars, after giving more than 300 scientists seed money to take an initial look at some far-out notions.

TOPICS:

Affymetrix Revenue Down 5%

October 28, 2010 4:55 am | News | Comments

Affymetrix, Inc., reported its operating results for the third quarter of 2010. Total revenue for the quarter was $74.0 million as compared to total revenue of $78.2 million in the third quarter of 2009.

TOPICS:

Elan Loses $43M In 3rd Quarter

October 28, 2010 4:52 am | News | Comments

Irish drugmaker Elan Corp. reported a third-quarter net loss as it paid down debts, cut research and development costs, and focused on increasing sales of drugs that combat multiple sclerosis.

TOPICS:

Emerging Markets Drive Sanofi Profits Up

October 28, 2010 4:49 am | by Greg Keller | News | Comments

French pharmaceutical company Sanofi-Aventis SA said its net profit rose 13 percent in the third quarter thanks to strong demand in emerging markets and acquisitions in the consumer health care field.

TOPICS:

AZ Profit Sinks on Seroquel Settlement

October 28, 2010 4:46 am | News | Comments

Pharmaceutical company AstraZeneca on Thursday reported a 27 percent drop in third-quarter profit as it set aside nearly half a billion dollars to settle claims that its anti-psychotic drug Seroquel has harmful side-effects.

TOPICS:

Bayer Earnings Jump 12%

October 28, 2010 4:45 am | by Geir Moulson | News | Comments

Bayer AG's third-quarter earnings rose 12 percent as sales of farm products and high-tech materials boosted revenue at the pharmaceutical and chemical company, helping balance out slower growth at its drug division.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading